NIOX Group Plc (CSSPF) Research

NIOX Group Plc operates as a medical technology company, specializing in global diagnostic and management solutions. It provides point-of-care products for the diagnosis and ongoing management of fractional exhaled nitric oxide (FeNO). A key offering is the NIOX VERO, a compact and portable system designed for the non-invasive measurement of nitric oxide levels in human breath. The company, established in 2006, was formerly known as Circassia Group Plc before rebranding to NIOX Group Plc in September 2022. Its headquarters are situated in Oxford, United Kingdom.

Market snapshot

Symbol
CSSPF
Price
$0.80
Day change
0.00%
Market cap
$244.9M
P/E ratio
35.18x
52-week range
0.75-0.92
Sector
Healthcare
Industry
Medical - Devices
Next earnings
in 3 months

Peer companies

  • Broncus Holding Corporation (BRNHF)
  • biote Corp. (BTMD)
  • Dialogue Health Technologies Inc. (DLHTF)
  • EKF Diagnostics Holdings plc (EKDHF)
  • Guerbet S.A. (GUERF)
  • Hamilton Thorne Ltd. (HTLZF)
  • Heyu Biological Technology Corporation (HYBT)
  • Opsens Inc. (OPSSF)

Open NIOX Group Plc (CSSPF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.